NEW YORK (GenomeWeb) – Kailos Genetics has signed an agreement to allow Illumina to market its TargetRich research solutions for pharmacogenetic target enrichment.

The products included in the marketing and promotions arrangement are TargetRich PGxComplete and Kailos Blue. According to Kailos, PGxComplete is a research use only reagent for targeting genes that are associated with response to more than 100 medications. Kailos Blue is the company's automated data analysis solution and reporting software used with TargetRich reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.